[
  {
    "the qustion": "A standard lipid panel includes measurements of TC, LDL, HDL, TG, and VLDL.",
    "a": "True",
    "b": "False",
    "c": "",
    "d": "",
    "correct": "a",
    "explanation": "A full lipid panel measures total cholesterol, LDL, HDL, triglycerides and VLDL. "
  },
  {
    "the qustion": "TC stands for \"Total Cholesterol\".",
    "a": "True",
    "b": "False",
    "c": "",
    "d": "",
    "correct": "a",
    "explanation": "TC is the abbreviation for total cholesterol. "
  },
  {
    "the qustion": "LDL means \"Low-Density Lipoprotein\" cholesterol.",
    "a": "True",
    "b": "False",
    "c": "",
    "d": "",
    "correct": "a",
    "explanation": "LDL stands for low-density lipoprotein cholesterol. "
  },
  {
    "the qustion": "HDL means \"High-Density Lipoprotein\" cholesterol.",
    "a": "True",
    "b": "False",
    "c": "",
    "d": "",
    "correct": "a",
    "explanation": "HDL is high-density lipoprotein cholesterol. "
  },
  {
    "the qustion": "VLDL refers to \"Very Low-Density Lipoprotein\" cholesterol.",
    "a": "True",
    "b": "False",
    "c": "",
    "d": "",
    "correct": "a",
    "explanation": "VLDL stands for very low-density lipoprotein cholesterol. "
  },
  {
    "the qustion": "Triglycerides are part of a standard lipid panel.",
    "a": "True",
    "b": "False",
    "c": "",
    "d": "",
    "correct": "a",
    "explanation": "Triglycerides (TG) are measured alongside cholesterol fractions. "
  },
  {
    "the qustion": "Patients generally need to fast 10–12 hours before a lipid panel.",
    "a": "True",
    "b": "False",
    "c": "",
    "d": "",
    "correct": "a",
    "explanation": "Most lipid panels require 10–12 h fasting (water only). "
  },
  {
    "the qustion": "Fasting before a lipid panel allows only water, no food or drink.",
    "a": "True",
    "b": "False",
    "c": "",
    "d": "",
    "correct": "a",
    "explanation": "Fasting means nothing but water. "
  },
  {
    "the qustion": "In some cases, a non-fasting lipid panel is acceptable.",
    "a": "True",
    "b": "False",
    "c": "",
    "d": "",
    "correct": "a",
    "explanation": "Non-fasting panels may be done when fasting isn’t feasible. "
  },
  {
    "the qustion": "If a patient eats during a fasting lipid panel, the results are still fully valid.",
    "a": "True",
    "b": "False",
    "c": "",
    "d": "",
    "correct": "b",
    "explanation": "Breaking fast reduces test utility; lab must be informed. "
  },
  {
    "the qustion": "Non-fasting intake affects HDL and Total Cholesterol measurements.",
    "a": "True",
    "b": "False",
    "c": "",
    "d": "",
    "correct": "b",
    "explanation": "HDL and TC are not affected by non-fasting. "
  },
  {
    "the qustion": "Severe primary hypercholesterolemia is LDL-C ≥190 mg/dL (≥4.9 mmol/L).",
    "a": "True",
    "b": "False",
    "c": "",
    "d": "",
    "correct": "a",
    "explanation": "LDL ≥190 mg/dL (4.9 mmol/L) defines severe primary hypercholesterolemia. "
  },
  {
    "the qustion": "You must calculate a 10-year ASCVD risk before starting high-intensity statin in LDL ≥190 mg/dL patients.",
    "a": "True",
    "b": "False",
    "c": "",
    "d": "",
    "correct": "b",
    "explanation": "Start high-intensity statin without calculating 10-year risk. "
  },
  {
    "the qustion": "High-intensity statin therapy generally reduces LDL-C by ≥50%.",
    "a": "True",
    "b": "False",
    "c": "",
    "d": "",
    "correct": "a",
    "explanation": "High-intensity statins lower LDL-C by ≥50%. "
  },
  {
    "the qustion": "Moderate-intensity statins typically reduce LDL-C by 30–49%.",
    "a": "True",
    "b": "False",
    "c": "",
    "d": "",
    "correct": "a",
    "explanation": "Moderate intensity yields ~30–49% LDL-C reduction. "
  },
  {
    "the qustion": "Simvastatin 20–40 mg/day is classified as high-intensity therapy.",
    "a": "True",
    "b": "False",
    "c": "",
    "d": "",
    "correct": "b",
    "explanation": "Simvastatin 20–40 mg is moderate-intensity. "
  },
  {
    "the qustion": "Atorvastatin 40–80 mg/day is high-intensity therapy.",
    "a": "True",
    "b": "False",
    "c": "",
    "d": "",
    "correct": "a",
    "explanation": "Atorvastatin 40–80 mg/day is high-intensity. "
  },
  {
    "the qustion": "Atorvastatin 10–20 mg/day is moderate-intensity therapy.",
    "a": "True",
    "b": "False",
    "c": "",
    "d": "",
    "correct": "a",
    "explanation": "Atorvastatin 10–20 mg/day is moderate-intensity. "
  },
  {
    "the qustion": "Rosuvastatin 20–40 mg/day is moderate-intensity therapy.",
    "a": "True",
    "b": "False",
    "c": "",
    "d": "",
    "correct": "b",
    "explanation": "Rosuvastatin 20–40 mg/day is high-intensity. "
  },
  {
    "the qustion": "Rosuvastatin 5–10 mg/day is moderate-intensity therapy.",
    "a": "True",
    "b": "False",
    "c": "",
    "d": "",
    "correct": "a",
    "explanation": "Rosuvastatin 5–10 mg/day is moderate-intensity. "
  },
  {
    "the qustion": "Simvastatin is marketed under the name Lipitor.",
    "a": "True",
    "b": "False",
    "c": "",
    "d": "",
    "correct": "b",
    "explanation": "Simvastatin’s brand is Zocor; Lipitor is atorvastatin. "
  },
  {
    "the qustion": "Rosuvastatin is marketed under the name Crestor.",
    "a": "True",
    "b": "False",
    "c": "",
    "d": "",
    "correct": "a",
    "explanation": "Crestor (and Rostar, Ezallor) is rosuvastatin. "
  },
  {
    "the qustion": "Ezetimibe is added if LDL-C remains ≥100 mg/dL on statin therapy.",
    "a": "True",
    "b": "False",
    "c": "",
    "d": "",
    "correct": "a",
    "explanation": "Add ezetimibe when LDL-C remains ≥100 mg/dL. "
  },
  {
    "the qustion": "Ezetimibe is first-line therapy for LDL-C ≥190 mg/dL.",
    "a": "True",
    "b": "False",
    "c": "",
    "d": "",
    "correct": "b",
    "explanation": "High-intensity statin is first-line for LDL ≥190 mg/dL. "
  },
  {
    "the qustion": "A PCSK9 inhibitor may be considered if LDL-C ≥100 mg/dL on statin + ezetimibe and multiple risk factors.",
    "a": "True",
    "b": "False",
    "c": "",
    "d": "",
    "correct": "a",
    "explanation": "Consider PCSK9 inhibitor in this scenario. "
  },
  {
    "the qustion": "Patients 40–75 years old with diabetes and LDL-C ≥70 mg/dL should start moderate-intensity statins.",
    "a": "True",
    "b": "False",
    "c": "",
    "d": "",
    "correct": "a",
    "explanation": "Moderate-intensity statins are indicated for diabetes + LDL ≥70. "
  },
  {
    "the qustion": "High-risk diabetic patients are not candidates for high-intensity statins.",
    "a": "True",
    "b": "False",
    "c": "",
    "d": "",
    "correct": "b",
    "explanation": "High-risk diabetics may reasonably use high-intensity statins. "
  },
  {
    "the qustion": "Statin response should be assessed 1–3 months after initiation or dose adjustment.",
    "a": "True",
    "b": "False",
    "c": "",
    "d": "",
    "correct": "a",
    "explanation": "Initial follow-up is recommended at 1–3 months. "
  },
  {
    "the qustion": "Once stable, lipid panels should be repeated every 3–12 months.",
    "a": "True",
    "b": "False",
    "c": "",
    "d": "",
    "correct": "a",
    "explanation": "Periodic monitoring every 3–12 months is advised. "
  },

  {
    "the qustion": "Which of the following is NOT part of a standard lipid panel?",
    "a": "HDL",
    "b": "LDL",
    "c": "RBC",
    "d": "VLDL",
    "correct": "c",
    "explanation": "Red blood cells are not measured in a lipid panel. "
  },
  {
    "the qustion": "TC is measured in which units?",
    "a": "mg/dL",
    "b": "mm Hg",
    "c": "mEq/L",
    "d": "IU/mL",
    "correct": "a",
    "explanation": "Cholesterol is reported in mg/dL. "
  },
  {
    "the qustion": "What’s the mmol/L equivalent of LDL-C ≥190 mg/dL?",
    "a": "4.9 mmol/L",
    "b": "1.8 mmol/L",
    "c": "3.2 mmol/L",
    "d": "5.2 mmol/L",
    "correct": "a",
    "explanation": "≥190 mg/dL equals ≥4.9 mmol/L. "
  },
  {
    "the qustion": "High-intensity statins aim for LDL-C reduction of at least:",
    "a": "30%",
    "b": "40%",
    "c": "50%",
    "d": "20%",
    "correct": "c",
    "explanation": "High-intensity reduces LDL-C by ≥50%. "
  },
  {
    "the qustion": "Moderate-intensity statins target LDL-C reduction of:",
    "a": "10–29%",
    "b": "30–49%",
    "c": "50–69%",
    "d": "70–89%",
    "correct": "b",
    "explanation": "Moderate-intensity yields ~30–49% reduction. "
  },
  {
    "the qustion": "Simvastatin brand name is:",
    "a": "Lipitor",
    "b": "Crestor",
    "c": "Zocor",
    "d": "Ezetrol",
    "correct": "c",
    "explanation": "Zocor is simvastatin’s trade name. "
  },
  {
    "the qustion": "Atorvastatin brand name is:",
    "a": "Zocor",
    "b": "Lipitor",
    "c": "Crestor",
    "d": "Lescol",
    "correct": "b",
    "explanation": "Lipitor is atorvastatin’s trade name. "
  },
  {
    "the qustion": "Rosuvastatin is sold as:",
    "a": "Lescol",
    "b": "Zocor",
    "c": "Crestor",
    "d": "Livalo",
    "correct": "c",
    "explanation": "Crestor (and Rostar/Ezallor) is rosuvastatin. "
  },
  {
    "the qustion": "Which dose of simvastatin is moderate-intensity?",
    "a": "5–10 mg",
    "b": "10–20 mg",
    "c": "20–40 mg",
    "d": "40–80 mg",
    "correct": "c",
    "explanation": "20–40 mg/day is moderate-intensity simvastatin. "
  },
  {
    "the qustion": "Which dose of atorvastatin is moderate-intensity?",
    "a": "5–10 mg",
    "b": "10–20 mg",
    "c": "20–40 mg",
    "d": "40–80 mg",
    "correct": "b",
    "explanation": "10–20 mg/day is moderate-intensity atorvastatin. "
  },
  {
    "the qustion": "Which dose of rosuvastatin is moderate-intensity?",
    "a": "5–10 mg",
    "b": "10–20 mg",
    "c": "20–40 mg",
    "d": "40–80 mg",
    "correct": "a",
    "explanation": "5–10 mg/day is moderate-intensity rosuvastatin. "
  },
  {
    "the qustion": "After starting statin, response should be checked at:",
    "a": "2–4 weeks",
    "b": "1–3 months",
    "c": "6 months",
    "d": "1 year",
    "correct": "b",
    "explanation": "Reassess 1–3 months after initiation or dose change. "
  },
  {
    "the qustion": "Stable lipid panels should then be repeated every:",
    "a": "1–2 months",
    "b": "3–12 months",
    "c": "12–18 months",
    "d": "2 years",
    "correct": "b",
    "explanation": "Monitor every 3–12 months thereafter. "
  },
  {
    "the qustion": "Ezetimibe acts by inhibiting:",
    "a": "HMG-CoA reductase",
    "b": "PCSK9",
    "c": "Cholesterol absorption",
    "d": "Lipoprotein lipase",
    "correct": "c",
    "explanation": "Ezetimibe blocks intestinal cholesterol absorption. "
  },
  {
    "the qustion": "PCSK9 inhibitors target:",
    "a": "HMG-CoA reductase",
    "b": "LDL receptor degradation",
    "c": "Cholesterol absorption",
    "d": "Triglyceride synthesis",
    "correct": "b",
    "explanation": "PCSK9 inhibitors prevent LDL receptor breakdown. "
  },
  {
    "the qustion": "Diabetic patients 40–75 with LDL ≥70 mg/dL start:",
    "a": "High-intensity statin",
    "b": "Moderate-intensity statin",
    "c": "Low-intensity statin",
    "d": "No statin",
    "correct": "b",
    "explanation": "Moderate-intensity statins are indicated. "
  },
  {
    "the qustion": "High-risk diabetics may reasonably use:",
    "a": "High-intensity statin",
    "b": "No statin",
    "c": "Ezetimibe monotherapy",
    "d": "PCSK9 inhibitor first-line",
    "correct": "a",
    "explanation": "High-intensity statins are reasonable in high-risk DM. "
  }
]